Optimizing AI for personalized medicine

PD Theranostics (PDTx) leverages proprietary workflows and methods utilizing imaging-based methodologies to diagnose and guide clinical decision making around specific targeted therapies and their efficacy in human disease states, including cancer, infectious diseases and complications of diabetes including diabetic foot ulcers

This has led to the development of an artificial intelligence (AI) driven theranostic that will guide both diagnostic and therapeutic decision making – involving the use of both unique tissue preparation kits and novel algorithms.

Our goal: Improve outcomes while reducing costs.

This approach could be applied to any disease in which diagnosis rests on the histopathological analysis of tissue biopsies

PDTx’s platform will be designed to determine the severity of the disease, aid in the refining the pathological diagnosis and optimal treatment decisions.

PD Theranostics at-a-glance

Lead Theragnostics Artificial Intelligence (AI) driven therapeutic decision-making tool
Focus
  • Developing algorithms in prostate cancer (PCa) and diabetic foot ulcers (DFUs) to help choose optimal treatment for a patient
Status
  • License and Sponsored Research Agreements in process with the Vaccine and Immunotherapy Center (VIC) at the Massachusetts General Hospital of Harvard university
  • Initial proof of concept completed in PCa & DFU
  • Enhanced algorithms to be developed; team assembled, including experienced AI leadership
  • Acquired a Hyperion Imaging Mass Cytometry device